Tenax Therapeutics Stock Alpha and Beta Analysis

TENX Stock  USD 5.36  0.03  0.56%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tenax Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tenax Therapeutics over a specified time horizon. Remember, high Tenax Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tenax Therapeutics' market risk premium analysis include:
Beta
1.01
Alpha
0.36
Risk
3.36
Sharpe Ratio
0.17
Expected Return
0.57
Please note that although Tenax Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Tenax Therapeutics did 0.36  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Tenax Therapeutics stock's relative risk over its benchmark. Tenax Therapeutics has a beta of 1.01  . Tenax Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Tenax Therapeutics is expected to follow. At this time, Tenax Therapeutics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Price Book Value Ratio is likely to rise to 0.71 in 2024, whereas Book Value Per Share is likely to drop 31.02 in 2024.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Tenax Therapeutics Backtesting, Tenax Therapeutics Valuation, Tenax Therapeutics Correlation, Tenax Therapeutics Hype Analysis, Tenax Therapeutics Volatility, Tenax Therapeutics History and analyze Tenax Therapeutics Performance.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Tenax Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tenax Therapeutics market risk premium is the additional return an investor will receive from holding Tenax Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tenax Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tenax Therapeutics' performance over market.
α0.36   β1.01

Tenax Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Tenax Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Tenax Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Tenax Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Tenax Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tenax Therapeutics shares will generate the highest return on investment. By understating and applying Tenax Therapeutics stock market price indicators, traders can identify Tenax Therapeutics position entry and exit signals to maximize returns.

Tenax Therapeutics Return and Market Media

The median price of Tenax Therapeutics for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 3.89 with a coefficient of variation of 14.6. The daily time series for the period is distributed with a sample standard deviation of 0.6, arithmetic mean of 4.1, and mean deviation of 0.54. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Tenax Therapeutics Now Covered by StockNews.com
09/20/2024
2
Tenax Therapeutics Research Coverage Started at William Blair
10/04/2024
3
Acquisition by Davidson Michael H. of 47500 shares of Tenax Therapeutics at 0.01 subject to Rule 16b-3
10/11/2024
4
Tenax Therapeutics Expands Stock Incentive Plan - TipRanks
10/30/2024
5
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
11/13/2024
6
Acquisition by Rich Stuart of 100000 shares of Tenax Therapeutics at 0.62 subject to Rule 16b-3
11/22/2024

About Tenax Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tenax or other stocks. Alpha measures the amount that position in Tenax Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Dividend Yield3.723.31
Price To Sales Ratio134.5K141.3K

Tenax Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Tenax Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tenax Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tenax Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tenax Therapeutics. Please utilize our Beneish M Score to check the likelihood of Tenax Therapeutics' management manipulating its earnings.
12th of February 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Tenax Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.